MetaVia's Lead Obesity Drug DA-1726 Achieves 9.1% Weight Loss in Phase 1, Secures Funding into Q4 2026
MTVA is trading near its 52-week low of $1.217 (6.8% above the low).
Summary
MetaVia Inc. announced its year-end 2025 financial results and a comprehensive corporate update, revealing highly positive Phase 1 data for its lead obesity asset, DA-1726. The drug demonstrated a significant 9.1% weight loss, improved glucose control, and direct liver benefits, positioning it as a potential best-in-class treatment. The company also reported $10.3 million in cash and cash equivalents, bolstered by a $9.3 million public offering in January, which is expected to fund operations into the fourth quarter of 2026. While the Institutional Review Board (IRB) approval for the Phase 1 Part 3 study was previously disclosed on March 18, the detailed clinical efficacy data and financial runway are new and highly material. This strong clinical progress and improved liquidity are significant for a clinical-stage biotechnology company. Investors will now watch for the initiation of the Phase 1 Part 3 study in April and the anticipated data release in Q4 2026.
At the time of this announcement, MTVA was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $1.22 to $23.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.